Mounjaro Doses and Supply: Understanding Which Doses of Mounjaro Are on Backorder

Last reviewed: July 16, 2026

Last updated: July 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Since its FDA approval in 2022, Mounjaro (tirzepatide) has faced recurring supply interruptions that leave patients searching for alternative sources. PlexusDx addresses these access barriers by offering compounded tirzepatide injection manufactured through licensed 503A compounding pharmacies, ensuring patients can maintain consistent treatment regardless of brand-name inventory fluctuations.

Why Mounjaro Supplies Face Ongoing Backorders

Mounjaro's exceptional demand has repeatedly strained Eli Lilly's manufacturing capacity. The medication addresses a significant gap in weight loss treatment options, driving prescription volumes that have exceeded production timelines multiple times since launch. Each backorder announcement creates uncertainty for patients already stabilized on their current dose, forcing delays in treatment progression or switches to alternative therapies.

Supply chain complexities compound the problem. Cold-chain logistics, regulatory oversight of injectable medications, and the precision required in manufacturing GLP-1 receptor agonists mean that production cannot simply scale overnight. Patients often discover mid-treatment that their scheduled refill is unavailable, disrupting their therapeutic momentum and potentially triggering weight regain.

Which Mounjaro Doses Have Been Most Affected

Backorder patterns have targeted specific dose strengths inconsistently. Earlier shortages hit maintenance doses (2.5 mg and higher), while some starter kits remained available. This fragmented supply picture forces prescribers to adjust treatment plans based on what's in stock rather than what's optimal for individual patients. Recent reports indicate that mid-range doses frequently face longer wait times than either the lowest or highest available strengths.

The unpredictability of which doses are affected makes planning difficult. A patient scheduled to titrate from 1.0 mg to 1.5 mg may find the latter unavailable, forcing them to either delay escalation or skip weeks of therapy. This disruption can slow weight loss progress and compromise metabolic adaptation benefits that rely on consistent weekly dosing.

How Compounded Tirzepatide Offers Consistent Access

PlexusDx compounded tirzepatide injection eliminates backorder uncertainty through partnerships with multiple licensed 503A compounding pharmacies. These facilities operate independently from Eli Lilly's supply chain, allowing them to maintain stock and fulfill prescriptions without the inventory constraints affecting retail pharmacies. Patients receive the same active ingredient with consistent quality oversight and regulatory compliance.

Compounding pharmacies prepare tirzepatide in individualized doses tailored to patient needs, reducing waste and ensuring exact therapeutic doses. PlexusDx's network model distributes demand across multiple licensed facilities, preventing single-source bottlenecks. Patients starting tirzepatide therapy through PlexusDx typically receive their first dose within one week, compared to weeks-long delays often experienced with brand-name products during shortage periods.

Cost and Coverage When Brand-Name Supply Fails

Mounjaro's brand-name pricing ($900–$1,350 monthly without insurance) creates additional access pressure when supply becomes unavailable. Patients caught in backorders cannot simply switch to competitors—tirzepatide is exclusive to Mounjaro, and generic alternatives do not exist. This leaves them paying list price for delayed medication or switching to less-effective alternatives.

PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan), reducing financial burden while eliminating supply delays. No membership fees apply, no insurance is required, and HSA/FSA funds cover treatment. Patients avoid the hidden cost of interrupted therapy: the weight regain, metabolic setback, and need to restart titration protocols when supply finally arrives. Switching to PlexusDx mid-treatment ensures continuity without price shock or additional out-of-pocket expense.

Personalization Through Precision Peptide Genetic Testing

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Patients using compounded tirzepatide through PlexusDx benefit from dosing flexibility that brand-name supply constraints prevent. If genetic testing reveals stronger GIPR pathway signaling, for example, compounding pharmacies can prepare individualized doses without waiting for pre-packaged pen availability. This precision approach means your dose can increase to match your biology—not your pharmacy's current inventory.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Mounjaro still on backorder in 2024?

Mounjaro supply remains inconsistent, with specific doses experiencing periodic unavailability. PlexusDx eliminates this uncertainty by offering compounded tirzepatide injection through licensed 503A pharmacies, ensuring consistent access at $289/month without backorder delays affecting your treatment timeline.

Can I switch from Mounjaro to compounded tirzepatide mid-treatment?

Yes. Compounded tirzepatide injection contains the same active ingredient and works identically to brand-name Mounjaro. Your prescriber can transfer your treatment to PlexusDx without restarting the titration protocol, maintaining your current dose and therapeutic progress while eliminating supply concerns.

Why is compounded tirzepatide so much cheaper than Mounjaro?

Compounded medications bypass brand-name manufacturing and marketing costs. PlexusDx sources from licensed 503A compounding pharmacies that prepare tirzepatide in individualized strengths, reducing overhead and passing savings directly to patients. Lower cost does not compromise quality—all medications meet USP compounding standards.

Will my insurance cover compounded tirzepatide from PlexusDx?

PlexusDx requires no insurance and no membership fees. Compounded tirzepatide is HSA/FSA eligible, allowing you to use tax-advantaged health accounts. Even without insurance, monthly pricing is $289/mo month-to-month, substantially lower than brand-name Mounjaro's typical cost.

What is the Precision Peptide Genetic Test, and does it improve outcomes?

The Precision Peptide Genetic Test analyzes 14 metabolic pathways and 150+ genetic insights affecting GLP-1 and tirzepatide response. It identifies variants in GIPR, GLP1R, FTO, and MC4R genes that influence your individual response pattern. This $99 add-on (after first month) helps PlexusDx optimize your personalized dosing strategy.

Related Reading

• Mounjaro Doses
• Hers Mounjaro
• Hims Mounjaro
• Mounjaro For Hypertension

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.